Investigation Report on China’s Recombinant Lispro Insulin Market, 2018-2022

$2,200$3,300

Description According to CRI, the rapid development of China’s economy in the past 30 years has brought about changes in people’s lifestyles, for example, the reduction in exercise and the rising intake of calories, which increases the incidence of diabetes. It is estimated that by the end of 2017, the number of diabetic patients in China had exceeded 100 million. For patients with Type 1 diabetes, insulin is the only effective treatment. In addition, 30% to 40% of patients with Type 2 diabetes eventually become insulin dependent. With the increasing … Continue reading Investigation Report on China’s Recombinant Lispro Insulin Market, 2018-2022

Read more